司来吉兰与普拉克索分别辅助多巴丝肼片治疗中晚期帕金森病的效果对比  

Effect comparison of Selegiline and Pramipexole respectively assisting on Levodopa and Benserazide Tablets in the treatment of middle and advanced Parkinson′s disease

作　　者：赖穗翩[1] 陈钜涛 黎冠东[1] LAI Sui-pian;CHEN Ju-tao;LI Guan-dong(Three Areas, Department of Neurology, Jiangmen Central Hospital, Guangdong Province, Jiangmen 529000, China)

机构地区：[1]广东省江门市中心医院神经内科三区,广东江门529000

出　　处：《中国当代医药》2019年第4期80-82,共3页China Modern Medicine

摘　　要：目的比较司来吉兰与普拉克索分别辅助多巴丝肼片改善中晚期帕金森病的效果。方法分析我院2014年7月～2017年6月收治的50例帕金森病患者临床资料,依据用药方案不同分为对照组(司来吉兰联合多巴丝肼片,25例)和观察组(普拉克索联合多巴丝肼片,25例),观察两组治疗前后帕金森病综合评分量表(UPDRS)评分和汉密尔顿抑郁量表(HAMD)评分情况,观察两组临床效果和不良反应发生率情况。结果两组治疗前UPDRS和HAMD评分比较,差异无统计学意义(P>0.05),两组治疗后UPDRS和HAMD评分均低于治疗前,观察组治疗后UPDRS和HAMD评分均低于对照组(P<0.05),观察组的临床治疗总有效率高于对照组,差异均有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论对中晚期帕金森病患者的治疗,普拉克索联合多巴丝肼片比司来吉兰的UPDRS和HAMD评分改善更明显,效果更良好。Objective To compare the effect of Selegiline and Pramipexole respectively assisting on Levodopa and Benserazide Tablets in the treatment of middle and advanced Parkinson′s disease. Methods The clinical data of 50 patients with Parkinson′s disease admitted to our hospital from July 2014 to June 2017 were analyzed. According to different medication regimens, they were equally divided into control group (Selegiline combined with Levodopa and Benserazide Tablets) and observation group (Pramipexole combined with Levodopa and Benserazide Tablets), 25 cases in each group. The unified parkinson′s disease rating scale (UPDRS) score and the Hamilton depression scale (HAMD) score before and after treatment were observed. The clinical effect and incidence of adverse reactions of the two groups were observed. Results The differences of UPDRS score and HAMD score between the two groups before treatment was not statistically significant (P>0.05). After treatment, the UPDRS score and HAMD score of the two groups were both lower than those before treatment (P<0.05). The UPDRS score and HAMD score of the observation group after treatment were both lower comarped with those in the control group (P<0.05). The total clinical effectiveness rate was higher in the observation group than that in the control group with statistical significance (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion For patients with middle and advanced Parkinson′s disease, the UPDRS score and the HAMD score are markedly improved with a better effect in Pramipexole combined with Levodopa and Benserazide Tablets compared with Selegiline combined with Levodopa and Benserazide Tablets.

关 键 词：司来吉兰 普拉克索 多巴丝肼片 中晚期帕金森病 

分 类 号：R742.5[医药卫生—神经病学与精神病学]